Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomised controlled trial.

By K. Fukase, Mototsugu Kato, S. Kikuchi, Kazuhiko Inoue, N. Uemura, S. Okamoto, S. Terao, K. Amagai, S. Hayashi, M. Asaka. The Lancet, 2008

1,207 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Management of precancerous conditions and lesions in the stomach (MAPS): guideline from the European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter Study Group (EHSG), European Society of Pathology (ESP), and the Sociedade Portuguesa de Endoscopia Digestiva (SPED) (2011, background): “pylori eradication and in a short period of time (3 years) [240, 241].”
Japanese gastric cancer treatment guidelines 2018 (5th edition) (2020, background): “Further investigations regarding this issue are warranted [31, 32].”
Gastric Cancer: Epidemiology, Risk Factors, Classification, Genomic Characteristics and Treatment Strategies (2020, background): “pylori eradication on the development of metachronous gastric carcinoma after the endoscopic resection of early GC [104].”
Association Between Helicobacter pylori Eradication and Gastric Cancer Incidence: A Systematic Review and Meta-analysis. (2016, background): “…(0.48-1.86) B NA Lee et al, 2013 Taiwan 59.9 31.7 8.4 0.94 (0.46-1.89) C T Studies on individuals after endoscopic resection of early gastric cancer (tertiary prevention) RCT Fukase et al, 2008 Japan 99.6 66.7 NA 0.38 (0.18-0.79) A or D T Choi et al, 2014 Korea 75.5 90.7 NA 0.61 (0.28-1.31) A…”